The occurrence of acute kidney injury (AKI) is rising in developed countries. The global incidence of AKI in inpatient facilities ranges from 0.7% to 31%, while it is more than 50% in intensive care unit (ICU) patients. A range from 3% to 13% patients having AKI need RRT and 40% of these patients are estimated to need CRRT for more than 90 days. AKI is associated with a 3- to 10-fold increase in inpatient death, and even among those who survive, the long-term effects are associated, such as risk for chronic kidney disease, cardiovascular disease, and all-cause mortality.
Increased Demand for Pediatric CRRT Devices Drives Continuous Renal Replacement Therapy Market
Continuous renal replacement therapy (CRRT) has become the recommended dialysis option for children admitted to ICUs for AKI treatments. The indications for renal replacement in the pediatric population have changed due to a wide range of pediatric diseases. The range of CRRT applications has expanded with its proven effectiveness in treating nonrenal indications, primarily, in critically ill newborns. For instance, the Carpediem system by Medtronic offers a dedicated extracorporeal CRRT for low-weight patients; as per the company’s claims, the device responds effectively to the needs of the most fragile patients. Moreover, PRISMASOL and PHOXILLUM solutions by Baxter are indicated as a replacement solution in CRRT to replace plasma volume removed by ultrafiltration as well as to correct electrolyte and acid-base imbalances in pediatric and adult patients. Thus, the increased demand for pediatric CRRT devices benefits the continuous renal replacement therapy market growth.
Continuous Renal Replacement Therapy Market: Regional Overview
The continuous renal replacement therapy market, by product, is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. By modality, the market is segmented into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). By end user, the market is segmented into hospitals, ambulatory care centers, home care, and others.
Continuous Renal Replacement Therapy Market: Regional Overview
In terms of geography, the continuous renal replacement therapy market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In terms of revenue, North America dominated the continuous renal replacement therapy market in 2022. The growing geriatric population, coupled with an upsurge in kidney disorder diagnoses among these people, is a key factor associated with the progress of the continuous renal replacement therapy market in North America. The increasing adoption of unhealthy food habits is one of the most prominent risk factor for numerous lifestyle-related disorders such as hypertension, diabetes, and kidney dysfunction. According to the US Department of Health and Human Services in 2021, 1 in 7 US adults were estimated to have CKD. Thus, the surging incidence of kidney-related disorders propels the market growth in North America.
The market in Asia Pacific is anticipated to register the highest CAGR in the continuous renal replacement therapy market during 2022–2030. The market growth in Asia Pacific is attributed to the improving healthcare infrastructure with rising healthcare expenditure, which supports the adoption of innovative CRRT technologies. Additionally, strategic initiatives by market players to expand their presence in Asia Pacific and collaborations with local healthcare providers drive the market growth in the region.
Continuous Renal Replacement Therapy Market: Competitive Landscape and Key Developments
Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. are among the leading companies operating in the continuous renal replacement therapy market. Market players focus on many organic and inorganic developments, which allows them to benefit from attractive business opportunities prevailing in the continuous renal replacement therapy market.
• In April 2022, the US Food and Drug Administration (FDA) provided 510(k) clearance for the ST Set by Baxter International Inc. for its use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors).
• In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. SURDIAL DX is a state-of-the-art hemodialysis system designed to create an optimal dialysis treatment experience for patients and clinicians. Manufactured in Japan, the product is based is based on over 35 years of expertise in renal device innovation at Nipro’s parent company, Nipro Corporation.
• In March 2021, B. Braun Avitum AG (a prime manufacturer of medical devices and pharmaceutical products and services) and CytoSorbents Corporation (a leading provider of critical care immunotherapy products) launched a global comarketing agreement to promote the use of CytoSorb, incorporated with B. Braun’s latest OMNI continuous blood purification platform and OMNIset Plus bloodline set (set version 3.0 or higher). CytoSorbents Corporation has been focusing on commercializing its CytoSorb blood purification technology to treat deadly inflammation in patients.